Who owns LBIO - LION BIOTECHNOLOGIES INC - COM based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

LION BIOTECHNOLOGIES INC - COM (LBIO) Institutional Ownership

Q: What is CUSIP 53619R102?

CUSIP 53619R102 is the security identifier used in SEC filing datasets for LBIO - LION BIOTECHNOLOGIES INC - COM.

CUSIP: 53619R102

13F Institutional Holders and Ownership History from Q1 2014 to Q2 2017

Type / Class: Equity / COM
Symbol: LBIO

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Investment Quick Answers

What is CUSIP 53619R102?
CUSIP 53619R102 identifies LBIO - LION BIOTECHNOLOGIES INC - COM in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Continue Investment Research

Latest 13F filings for new institutional portfolio disclosures.
Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
Latest 10-Q/10-K reports to cross-check issuer fundamentals.
Recent insider transactions for management buying/selling context.
SEC investors directory and top value investors for manager-level discovery.
All institutional ownership pages to compare adjacent CUSIP pages.

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 53619R102:

Q2 2017 (0 holders) Q1 2017 (79 holders) Q4 2016 (85 holders) Q3 2016 (91 holders) Q2 2016 (81 holders) Q1 2016 (77 holders) Q4 2015 (80 holders) Q3 2015 (78 holders) Q2 2015 (85 holders) Q1 2015 (50 holders)

Institutional Holders of LION BIOTECHNOLOGIES INC - COM (LBIO) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2017 Q2	0	$0	-$360,753,785	$0	$0		0
2017 Q1	48,530,675	$361,235,782	+$36,798,947	$137,000	$1,048,000	$7.45	79
2016 Q4	49,674,408	$345,167,713	+$15,969,597	$1,912,000	$1,900,000	$6.95	85
2016 Q3	47,204,064	$388,401,235	+$42,926,877	$1,561,000	$1,084,000	$8.23	91
2016 Q2	44,204,795	$357,066,557	+$66,238,721	$2,761,000	$666,000	$8.10	81
2016 Q1	36,457,791	$185,175,000	+$4,598,545	$182,000	$2,429,000	$5.08	77
2015 Q4	35,321,668	$272,681,447	+$6,740,395	$187,000	$3,480,000	$7.72	80
2015 Q3	34,474,489	$198,567,433	+$6,108,708	$203,000	$392,000	$5.76	78
2015 Q2	35,495,544	$325,493,367	+$86,742,239	$886,000	$432,000	$9.17	85
2015 Q1	25,887,185	$313,492,000	+$206,309,035			$12.11	50
2014 Q4	3,215,549	$25,306,000	+$2,354,953			$7.93	2
2014 Q3	2,916,401	$20,852,000	-$681,549			$6.48	4
2014 Q2	3,011,721	$19,274,000	+$74,910			$6.11	2
2014 Q1	3,000,000	$28,320,000	+$28,320,000			$9.44	1